The feasibility and acceptability of a home-based, virtual exercise intervention for older patients with hepatocellular carcinoma: protocol for a non-randomised feasibility study (TELEX-Liver Cancer).
Exercise intervention
Feasibility
Liver cancer
Quality of life
Telehealth
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
27 May 2022
27 May 2022
Historique:
received:
13
10
2021
accepted:
17
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
The number of incident cases and deaths from primary liver cancer, predominantly hepatocellular carcinoma (HCC), has increased markedly in the last two decades. HCC is generally diagnosed at an advanced stage, and most new cases are in people aged over 70 years with age-related comorbidities. Treatment options are often limited, with most patients receiving palliative treatment or supportive care only. As a consequence, maintaining quality of life (QoL) through symptom management is critically important and is a core objective of clinical care. Strong evidence supports the efficacy of supervised exercise training for addressing certain cancer-related symptoms, including QoL, physical function, and fatigue. However, there are many barriers to implementing supervised exercise programmes within cancer care pathways, including economic pressures on healthcare systems and personal barriers for patients. Recent advances in technology allow patients to exercise at home under the 'virtual' supervision of an exercise professional through videoconferencing software (termed 'telehealth exercise'). Despite its potential, there are uncertainties relating to the feasibility, acceptability, and safety of telehealth exercise in people living with HCC. This is a protocol for a prospective, single-centre, single-arm, pretest-posttest feasibility trial. We aim to recruit 20 patients aged 60 years or older who have received treatment for HCC and are undergoing routine clinical monitoring. Patients will be invited to take part in two online, home-based, group exercise sessions per week for 10 consecutive weeks. The 'virtual' exercise sessions will be delivered in real time by an exercise professional through videoconferencing software. Each session will comprise 30 min of aerobic and resistance exercise performed at a moderate intensity, as guided by the 10-point Borg rating of perceived exertion scale. Feasibility outcomes include recruitment, retention, adherence, intervention fidelity, and safety. Acceptability of the intervention will be assessed using a mixed-methods approach via monthly online surveys and an exit telephone interview. Physical function, accelerometry-measured physical activity, mid-upper arm circumference, and patient-reported outcome measures (PROMS) will be assessed before and after the intervention to determine the feasibility of assessing outcome measures. Physical function outcomes include the short physical performance battery and Liver Frailty Index. PROMS include the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire, Activities-specific Balance Confidence scale, Hospital Anxiety and Depression Scale, and the Godin Leisure-Time Exercise Questionnaire. This mixed-methods study will address uncertainties relating to the feasibility and acceptability of delivering live, online, home-based, group exercise sessions to patients with HCC. The findings will inform whether any modifications are required to refine and optimise the intervention, and the assessment of outcome measures will provide information on the likely size and variability of intervention effects. Collectively, the data generated will inform the design of a subsequent, adequately powered, randomised controlled trial to evaluate the efficacy of the telehealth exercise intervention. ISRCTN14411809.
Sections du résumé
BACKGROUND
BACKGROUND
The number of incident cases and deaths from primary liver cancer, predominantly hepatocellular carcinoma (HCC), has increased markedly in the last two decades. HCC is generally diagnosed at an advanced stage, and most new cases are in people aged over 70 years with age-related comorbidities. Treatment options are often limited, with most patients receiving palliative treatment or supportive care only. As a consequence, maintaining quality of life (QoL) through symptom management is critically important and is a core objective of clinical care. Strong evidence supports the efficacy of supervised exercise training for addressing certain cancer-related symptoms, including QoL, physical function, and fatigue. However, there are many barriers to implementing supervised exercise programmes within cancer care pathways, including economic pressures on healthcare systems and personal barriers for patients. Recent advances in technology allow patients to exercise at home under the 'virtual' supervision of an exercise professional through videoconferencing software (termed 'telehealth exercise'). Despite its potential, there are uncertainties relating to the feasibility, acceptability, and safety of telehealth exercise in people living with HCC.
METHODS
METHODS
This is a protocol for a prospective, single-centre, single-arm, pretest-posttest feasibility trial. We aim to recruit 20 patients aged 60 years or older who have received treatment for HCC and are undergoing routine clinical monitoring. Patients will be invited to take part in two online, home-based, group exercise sessions per week for 10 consecutive weeks. The 'virtual' exercise sessions will be delivered in real time by an exercise professional through videoconferencing software. Each session will comprise 30 min of aerobic and resistance exercise performed at a moderate intensity, as guided by the 10-point Borg rating of perceived exertion scale. Feasibility outcomes include recruitment, retention, adherence, intervention fidelity, and safety. Acceptability of the intervention will be assessed using a mixed-methods approach via monthly online surveys and an exit telephone interview. Physical function, accelerometry-measured physical activity, mid-upper arm circumference, and patient-reported outcome measures (PROMS) will be assessed before and after the intervention to determine the feasibility of assessing outcome measures. Physical function outcomes include the short physical performance battery and Liver Frailty Index. PROMS include the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire, Activities-specific Balance Confidence scale, Hospital Anxiety and Depression Scale, and the Godin Leisure-Time Exercise Questionnaire.
DISCUSSION
CONCLUSIONS
This mixed-methods study will address uncertainties relating to the feasibility and acceptability of delivering live, online, home-based, group exercise sessions to patients with HCC. The findings will inform whether any modifications are required to refine and optimise the intervention, and the assessment of outcome measures will provide information on the likely size and variability of intervention effects. Collectively, the data generated will inform the design of a subsequent, adequately powered, randomised controlled trial to evaluate the efficacy of the telehealth exercise intervention.
TRIAL REGISTRATION
BACKGROUND
ISRCTN14411809.
Identifiants
pubmed: 35624520
doi: 10.1186/s40814-022-01069-1
pii: 10.1186/s40814-022-01069-1
pmc: PMC9135985
doi:
Types de publication
Journal Article
Langues
eng
Pagination
113Subventions
Organisme : Cancer Research UK
ID : 26813
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C9380/A26813
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C18342/A23390
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Liver Cancer. 2020 Sep;9(5):563-582
pubmed: 33083281
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Med Sci Sports Exerc. 2011 Jul;43(7):1334-59
pubmed: 21694556
Transl Behav Med. 2021 Mar 16;11(2):314-322
pubmed: 33447852
J Cancer Surviv. 2019 Oct;13(5):703-712
pubmed: 31347009
BMC Geriatr. 2020 Jul 13;20(1):242
pubmed: 32660438
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Gait Posture. 2020 Feb;76:409-414
pubmed: 31945676
Phys Ther. 2010 Apr;90(4):550-60
pubmed: 20203094
Front Physiol. 2017 Jan 10;7:681
pubmed: 28119626
J Gerontol A Biol Sci Med Sci. 1998 Jul;53(4):M287-94
pubmed: 18314568
Trials. 2013 Dec 18;14:436
pubmed: 24351063
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390
pubmed: 31626055
Clin Interv Aging. 2021 May 25;16:973-983
pubmed: 34079243
Eur J Clin Nutr. 2010 Aug;64(8):899-904
pubmed: 20502470
Palliat Support Care. 2019 Dec;17(6):686-696
pubmed: 31109383
J Clin Oncol. 2017 Nov 10;35(32):3635-3637
pubmed: 28915086
J Appl Gerontol. 2015 Apr;34(3):377-96
pubmed: 25765822
Oncol Nurs Forum. 2013 Jan;40(1):44-52
pubmed: 23269769
J Oncol Pract. 2017 Jun;13(6):356-364
pubmed: 28605614
BMC Med Res Methodol. 2015 Aug 12;15:60
pubmed: 26264621
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Support Care Cancer. 2021 Nov;29(11):6369-6378
pubmed: 33885962
Int J Behav Nutr Phys Act. 2021 Apr 6;18(1):50
pubmed: 33823832
J Clin Oncol. 2002 May 1;20(9):2229-39
pubmed: 11980994
Semin Oncol Nurs. 2020 Dec;36(6):151092
pubmed: 33223409
J Gerontol A Biol Sci Med Sci. 1995 Jan;50A(1):M28-34
pubmed: 7814786
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Med Sci Sports Exerc. 1998 May;30(5):777-81
pubmed: 9588623
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Psychooncology. 2009 Apr;18(4):412-21
pubmed: 19241491
Hepatology. 2017 Aug;66(2):564-574
pubmed: 28422306
Oncologist. 2012;17(5):732-9
pubmed: 22511265
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
JAMA Intern Med. 2018 Oct 1;178(10):1301-1310
pubmed: 30208396
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Psychooncology. 2009 Apr;18(4):422-8
pubmed: 19243089
Circulation. 2007 May 1;115(17):2358-68
pubmed: 17468391
Hepatol Res. 2020 Mar;50(3):330-341
pubmed: 31721387
PLoS One. 2020 Jun 17;15(6):e0232371
pubmed: 32555707
J Natl Cancer Inst Monogr. 2004;(32):17-21
pubmed: 15263036
Phys Ther. 2020 Sep 28;100(10):1713-1716
pubmed: 32737965